| | The clinical content of preconception care: genetics and genomicsReceived 17 June 2008; received in revised form 22 September 2008; accepted 25 September 2008. The prevalence of paternal and maternal genetic conditions that affect pregnancy varies according to many factors that include parental age, medical history, and family history. Although some genetic conditions that affect pregnancy are identified easily early in life, other conditions are not and may require additional diagnostic testing. A complete 3-generation family medical history that includes ethnicity information about both sides of the family is arguably the single best genetic “test” that is applicable to preconception care. Assessment of genetic risk by an experienced professional has been shown to improve the detection rate of identifiable risk factors. Learning about possible genetic issues in the preconception period is ideal, because knowledge permits patients to make informed reproductive decisions. Options that are available to couples before conception include adoption, surrogacy, use of donor sperm, in vitro fertilization after preimplantation genetic diagnosis, and avoidance of pregnancy. Future technologic advances will increase the choices that are available to couples. Applications of genetics (the scientific study of heredity) and genomics (the study of an organism's complete genetic makeup) are expanding into virtually every sphere of healthcare; preconception care is no exception. However, the evidence-based application of genetics and genomics to preconception care is a work in progress for several reasons. First, less research attention has been given to genetic and genomic interventions in the preconception setting than to those in the prenatal period. Second, conducting prospective randomized trials in either the prenatal or preconception period is problematic ethically and legally. Finally, genetic technologies are emerging at a mind-numbing pace, and time will be required to develop evidence to support their utility. Despite the rapid evolution of this field, individuals who provide medical care to any person who is considering pregnancy should be aware of recommendations for genetic care in the preconception and prenatal period.1, 2 Some recommendations apply to all individuals. Other recommendations are more important for patients with specific risk factors. In many cases, these recommendations draw heavily on consensus and expert opinion. Additionally, most prenatal care guidelines have been extrapolated to the preconception period. Logically, this makes sense; however, formal studies that demonstrate the validity of this extrapolation are lacking and likely will never be completed. One final caveat is that the diversity and rarity of many genetic disorders that affect pregnancy ensure that any document that contains recommendations, including this one, will be incomplete. All individuals  Obtaining a complete 3-generation family medical history that includes ethnicity information about both sides of the family is arguably the single best genetic “test” that is applicable to preconception care. Additionally, a discussion of obstetric and medical history and parental age at anticipated delivery are critical aspects of a preconception healthcare visit. Family history and other historic data provide an inexpensive and noninvasive assessment of conditions that might affect pregnancy. Learning about these risks in the preconception period is ideal. Improved knowledge about the heritability of a disorder can allow individuals to make informed reproductive decisions and can improve prenatal care during pregnancy. Options that are available to couples before conception include adoption, surrogacy, use of donor sperm, preimplantation genetic diagnosis after in vitro fertilization with transfer of unaffected embryos, and avoidance of pregnancy. Future technologic advances likely will broaden further the choices that will be available to couples.3, 4, 5, 6, 7 Providers of preconception care should also urge women to take a multivitamin, with at least 400 μg of folate, daily beginning at least 1 month before conception. Folate has been shown to reduce the incidence of neural tube defects and may also reduce the incidence of other malformations such as orofacial clefting, limb deficiencies, cardiac defects, urinary tract defects, and omphalocele. Women with a history of medical conditions such as epilepsy or diabetes mellitus or a previous gestation with a neural tube defect may require increased folate intake.8, 9, 10 Finally, in addition to the testing discussed in Table 1, all couples, regardless of ethnicity, should be made aware of the availability of cystic fibrosis–carrier screening.11 | | |  | Ethnicity (of at least 1 member of the couple) | Disorders with recommended counseling/testing | Type of test |  |
|---|
 | White | Cystic fibrosisa | DNA testing of CFTR gene11 |  |  | European | Cystic fibrosisa | DNA testing of CFTR gene11 |  |  | Ashkenazi Jewish | Canavan disease, cystic fibrosis,a familial dysautonomia, Tay-Sachs disease, Gaucher's disease, Niemann-Pick disease Type A, Bloom syndrome, mucolipidosis IV, Fanconi anemia Group C | Canavan disease: DNA testing of ASPA gene13, 15, 19 |  |  | Cystic fibrosis: DNA testing of CFTR gene11, 13, 15, 19, 20 |  |  | Familial dysautonomia: DNA testing of IKBKAP gene13, 15, 19 |  |  | Tay-Sachs disease: enzyme assay for hexosaminidase-A level or DNA testing of HEXA gene13, 15, 19 |  |  | Gaucher's disease: DNA testing of GBA gene13, 15, 19 |  |  | Niemann-Pick disease Type A: DNA testing of SMPD1 gene13, 15, 19 |  |  | Bloom syndrome: DNA testing of BLM gene13, 15, 19 |  |  | Mucolipidosis IV: DNA testing of MCOLN1 gene13, 15, 19 |  |  | Fanconi anemia Group C: DNA testing of FANCC gene13, 15, 19 |  |  | French-Canadian | Tay-Sachs disease | Enzyme assay for hexosaminidase-A level or DNA testing of HEXA gene12, 14, 19 |  |  | Cajun | Tay-Sachs disease | Enzyme assay for hexosaminidase-A level or DNA testing of HEXA gene12, 14, 19 |  |  | African | Sickle cell disease/trait, thalassemia | Complete blood count with red blood cell indices (RBC), iron indices, hemoglobin electrophoresis16, 17, 18 |  |  | Mediterranean | Thalassemia | Complete blood count with red blood cell indices and iron indices; hemoglobin electrophoresis if anemia and normal iron indices16, 17, 18 |  |  | Asian | Thalassemia | Complete blood count with red blood cell indices and iron indices; hemoglobin electrophoresis if anemia and normal iron indices; DNA testing of alpha-globin genes for alpha thalassemia if Southeast Asian with low mean corpuscular volume anemia but normal iron studies16, 17, 18 |  | | | |
| a Cystic fibrosis should be discussed with patients of all races/ethnicities. |
Recommendation All women who are considering pregnancy should have a screening history in the preconception visit. Providers should ask about risks to pregnancy that are based on maternal age, maternal and paternal medical conditions, obstetric history, and family history. Ideally, a 3-generation family medical history should be obtained for both members of the couple with the goal of identifying known genetic disorders, congenital malformations, developmental delay/mental retardation, and ethnicity. If this screening history indicates the possibility of a genetic disease, specific counseling should be given that may include referral to a genetic counselor or clinical geneticist. Strength of recommendation: B; quality of evidence: III. All women should take a multivitamin with at least 400 μg of folate daily, starting at least 1 month before conception. Women with specific risk factors may require higher daily dosages of folate. Strength of recommendation: A; quality of evidence: II-2. All couples should be made aware of the availability of cystic fibrosis–carrier screening. Strength of recommendation: B; quality of evidence: III. Couples with ethnicity-based genetic risk factors  Ancestry influences the probability of being a carrier of many disorders that affect pregnancy. Typically, carriers themselves will not show any signs of a genetic disorder, and there is often no known family history of the condition. The guidelines for testing by ethnicity include conditions for which there is evidence that testing is effective or for which there is strong expert opinion that testing should be performed. However, this is not meant to imply that these conditions do not occur or should be ignored in populations of other ethnicities. Individuals of mixed ancestry or ethnicity should consider carrier testing that is recommended for any component ethnicity. A formal referral could be considered if practitioners are unsure which disorders should be tested. Table 1 contains a summary of counseling/testing by ethnicity.11, 12, 13, 14, 15, 16, 17, 18, 19, 20 Carrier testing can have important psychologic consequences for an individual and should only occur after informed consent is obtained. Choosing the appropriate test and interpreting results of testing can be complex and may vary between different ethnic groups. For example, with the current recommended mutation panel, negative carrier testing for cystic fibrosis in an Ashkenazi Jewish couple would result in a different chance of having an affected child than negative testing in an African American couple. Depending on the provider's proficiency in genetics, carrier testing may necessitate referral to genetic services.11, 13, 15, 19, 20 Recommendation Couples who are at risk for any ethnicity-based conditions should be offered preconception counseling about the risks of that condition to future pregnancies. Screening and/or testing should be offered based on the couple's preferences. This may require referral to a genetic counselor or clinical geneticist. Strength of recommendation: B; quality of evidence: II-3. Couples with genetic risk factors that are based on specific family history  If at least 1 member of a couple has a family history of developmental delay, congenital anomalies, or other known or suspected genetic conditions, the couple should be referred to a qualified healthcare provider for appropriate counseling and potential testing.2, 4 If a disorder in the individual's family has been identified as having a genetic cause, it may be possible to test an individual to determine whether the couple is at risk for having an affected child. For example, a family history of known genetic conditions such as cystic fibrosis or Tay-Sachs disease should prompt the offer of testing for at least the person with affected relatives. If the person is found to have inherited a gene that could cause the disorder in their children, the partner could be tested to quantify the overall risk. In the case of an X-linked disorder such as hemophilia, sex selection should be discussed.2, 21, 22, 23, 24, 25, 26 Table 2 gives information about examples of family history findings that should prompt further counseling/testing.  | Chromosomal disorders (eg, Trisomy 21) |  |  | Clotting disorders |  |  | Deafness |  |  | Developmental delay/mental retardation (eg, Fragile X syndrome) |  |  | Early infant death |  |  | Heart defects |  |  | Other known genetic disorders (eg, phenylketonuria, Marfan syndrome) |  |  | Neural tube defects |  |  | Familial cancer syndromes (known or suspected) |  |  | Family history of other congenital malformations |  |  | Neural tube defects |  |  | Orofacial clefts |  |  | Recurrent miscarriages |  |  | Sickle cell disease or trait |  |  | Sudden infant death syndrome |  |  | Thalassemia |  |  | Thrombophilia |  | | | |
Recommendation Individuals who are identified as having a family history of developmental delay, congenital anomalies, or other genetic disorders should be offered a referral to an appropriate specialist to better quantify the risk to a potential pregnancy. Strength of recommendation: B; quality of evidence: II-3. Couples with genetic risk factors that are based on previous pregnancies  A history of recurrent pregnancy loss (classically defined as > 2 spontaneous abortions) should prompt testing of both parents for genetic conditions such as chromosomal anomalies and hereditary thrombophilia.17, 27, 28 Testing for chromosomal anomalies can be performed by a test of peripheral blood for chromosome analysis (karyotyping).2 If a chromosomal anomaly such as a balanced translocation is found, providers should discuss the use of in vitro fertilization with preimplantation genetic diagnosis to increase the chance of an unaffected pregnancy.29, 30, 31 Recommendation If at least 1 member of a couple is found to have a chromosomal anomaly, in vitro fertilization with preimplantation genetic diagnosis should be discussed. Strength of recommendation: C; quality of evidence: III. Individuals with risk factors caused by known genetic conditions  Individuals with known genetic conditions should be counseled regarding optimal control of their condition and the chances of having affected offspring; these individuals should be aware of how the presence of a genetic disorder could affect both their health and the health of the fetus. For example, women with sickle cell disease have an increased risk of preterm labor and premature rupture of membranes; women with Marfan syndrome have an increased risk of aortic dissection during pregnancy.32, 33 In certain genetic disorders, there are specific recommendations for management in the preconception period. For example, women with sickle cell disease require increased amounts of folate; women with phenylketonuria should maintain low phenylalanine diets before conception, because infants who are born to women with phenylketonuria with phenylalanine levels of > 20 mg/dL are more likely to have microcephaly, developmental delay, growth restriction, and heart defects.17, 34, 35 Recommendation Suspected genetic disorders may require further work-up before conception. Known or discovered genetic conditions should be managed optimally before and after conception. Strength of recommendation: B; quality of evidence: II-3. Comment  No provider is expected to be aware of every genetic condition that possibly could affect a pregnancy; however, it is important that all providers be able to do 2 things. First, providers should be able to ask the right questions to determine who might be at risk. This includes the ability to take a 3-generation family history. Second, providers should know when to refer a patient and to whom a patient should be referred. There is a wide array of excellent educational resources regarding genetic disorders and family history that are available on the web. Table 3 contains a list of resources. Finally, providers should keep in mind that this is a very rapidly expanding field. Researchers are unraveling the genetic causes of many conditions for which screening and testing may soon become available.36 | | |  | Resources | Comments |  |
|---|
 | American College of Medical Genetics (www.acmg.net) | Includes links to the latest standards and guidelines for clinical genetics laboratories, with disease/phenotype-specific standards and guidelines |  |  | CDC National Office of Public Health Genomics (cdc.gov/genomics) | Resources on how human genomic discoveries can be used to improve health and prevent disease |  |  | Gene tests (genetests.org) | Reviews about specific conditions, laboratory and clinical directories, handouts for patients |  |  | Genetic Alliance (geneticalliance.org) | Information about specific disorders and advocacy, support, and discussion groups |  |  | Genetic and Rare Diseases Information Center (rarediseases.info.nih.gov/html/resources/info_cntr.html) | Information about specific disorders, explanations for patients, financial assistance information, and access to specialists |  |  | National Society of Genetic Counselors (nsgc.org) | Directory of genetic counselors, guidelines for counseling specific conditions |  |  | Online Mendelian Inheritance in Man (ncbi.nlm.nih.gov/sites/entrez?db=omim) | Searchable database of genes and genetic disorders that targets healthcare professionals |  |  | PubMed (ncbi.nlm.nih.gov/PubMed) | Medical literature database |  |  | US Surgeon General's Family History Initiative (hhs.gov/familyhistory) | Education about family health history through tools such as My Family Health Portrait |  | | | |
Acknowledgments  We thank Siobhan Dolan, MD, MPH, and Alan Guttmacher, MD, for their critical reviews and commentary on the article. References  1. 1American College of Obstetricians and Gynecologists. ACOG committee opinion no.: 313: the importance of preconception care in the continuum of women's health care. Obstet Gynecol. 2005;106:665–666. MEDLINE 2. 2Dolan SM, Moore C. Linking family history in obstetric and pediatric care: assessing risk for genetic disease and birth defects. Pediatrics. 2007;120(Suppl 2):S66–S70. 3. 3Koscica KL, Canterino JC, Harrigan JT, Dalaya T, Ananth CV, Vintzileos AM. Assessing genetic risk: comparison between the referring obstetrician and genetic counselor. Am J Obstet Gynecol. 2001;185:1032–1034. Abstract | Full Text |
Full-Text PDF (55 KB)
|
CrossRef
4. 4Hogge JS, Hogge WA. Preconception genetic counseling. Clin Obstet Gynecol. 1996;39:751–762. MEDLINE |
CrossRef
5. 5Wattendorf DJ, Hadley DW. Family history: the three-generation pedigree. Am Fam Physician. 2005;72:441–448. 6. 6Pellestor F, Andréo B, Anahory T, Hamamah S. The occurrence of aneuploidy in human: lessons from the cytogenetic studies of human oocytes. Eur J Med Genet. 2006;49:103–116. MEDLINE |
CrossRef
7. 7Schrander-Stumpel C. Preconception care: challenge of the new millennium?. Am J Med Genet. 1999;89:58–61. MEDLINE |
CrossRef
8. 8Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet. 2004;125:12–21. MEDLINE 9. 9Blom HJ, Shaw GM, den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci. 2006;7:724–731. 10. 10Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003–1026. 11. 11Committee on Genetics, American College of Obstetricians and Gynecologists. ACOG committee opinion no.: 325, December 2005: update on carrier screening for cystic fibrosis. Obstet Gynecol. 2005;106:1465–1468. MEDLINE 12. 12Kaplan F. Tay-Sachs disease carrier screening: a model for prevention of genetic disease. Genet Test. 1998;2:271–292. MEDLINE |
CrossRef
13. 13ACOG Committee on Genetics. ACOG committee opinion no.: 298, August 2004: prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 2004;104:425–428. MEDLINE 14. 14ACOG Committee on Genetics. ACOG committee opinion no.: 318, October 2005: screening for Tay-Sachs disease. Obstet Gynecol. 2005;106:893–894. MEDLINE 15. 15Gross SJ, Pletcher BA, Monaghan KGProfessional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008;10:54–56.
CrossRef
16. 16Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am. 2002;29:305–328. Full Text |
Full-Text PDF (353 KB)
|
CrossRef
17. 17ACOG Committee. ACOG practice bulletin no.: 64: clinical management guidelines for obstetrician-gynecologists (replaces committee opinion no.: 238, July 2000): hemoglobinopathies in pregnancy. Obstet Gynecol. 2005;106:203–210. MEDLINE 18. 18Rappaport VJ, Velazquez M, Williams K. Hemoglobinopathies in pregnancy. Obstet Gynecol Clin North Am. 2004;31:287–317. Full Text |
Full-Text PDF (309 KB)
|
CrossRef
19. 19Monaghan KG, Feldman GL, Palomaki GE, Spector EBAshkenazi Jewish Reproductive Screening Working Group; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med. 2008;10:57–72.
CrossRef
20. 20American College of Medical Genetics. Technical standards and guidelines for CFTR mutation testing. 2006. http://www.acmg.net/Pages/ACMGActiviites/stds-2002/cf.htm. 21. 21Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007;87:456–465. Abstract | Full Text |
Full-Text PDF (238 KB)
|
CrossRef
22. 22Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med. 2005;7:584–587. MEDLINE |
CrossRef
23. 23Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G. Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat Diagn. 2007;27:991–994.
CrossRef
24. 24Shaffer LGAmerican College of Medical Genetics, Professional Practice and Guidelines Committee. American College of Medical Genetics guideline on the cytogenetic evaluation of the individual with developmental delay or mental retardation. Genet Med. 2005;7:650–654. MEDLINE |
CrossRef
25. 25Vallance H, Ford J. Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci. 2003;40:473–497. MEDLINE |
CrossRef
26. 26Michaelides K, Tuddenham EG, Turner C, Lavender B, Lavery SA. Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. Thromb Haemost. 2006;95:373–379. MEDLINE 27. 27American College of Obstetricians and Gynecologists. ACOG practice bulletin no.: 24: management of recurrent pregnancy loss (replaces technical bulletin no.: 212, September 1995). Int J Gynaecol Obstet. 2002;78:179–190.
Full-Text PDF (7135 KB)
|
CrossRef
28. 28Dunlop AL, Jack BW, Bottalico JN, et al. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol. 2008;199:S310–S327. Abstract | Full Text |
Full-Text PDF (252 KB)
|
CrossRef
29. 29Escudero T, Lee M, Stevens J, Sandalinas M, Munne S. Preimplantation genetic diagnosis of pericentric inversions. Prenat Diagn. 2001;21:760–766. MEDLINE |
CrossRef
30. 30Munne S, Scott R, Sable D, Cohen J. First pregnancies after preconception diagnosis of translocations of maternal origin. Fertil Steril. 1998;69:675–681. Abstract | Full Text |
Full-Text PDF (277 KB)
|
CrossRef
31. 31Munne S, Sandalinas M, Escudero T, Fung J, Gianaroli L, Cohen J. Outcome of preimplantation genetic diagnosis of translocations. Fertil Steril. 2000;73:1209–1218. Abstract | Full Text |
Full-Text PDF (228 KB)
|
CrossRef
32. 32Powars DR, Sandhu M, Niland-Weiss J, Johnson C, Bruce S, Manning PR. Pregnancy in sickle cell disease. Obstet Gynecol. 1986;67:217–228. MEDLINE |
CrossRef
33. 33Lind J, Wallenburg HC. The Marfan syndrome and pregnancy: a retrospective study in a Dutch population. Eur J Obstet Gynecol Reprod Biol. 2001;98:28–35. Abstract | Full Text |
Full-Text PDF (94 KB)
|
CrossRef
34. 34Rouse B, Azen C. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr. 2004;144:235–239. Abstract | Full Text |
Full-Text PDF (238 KB)
|
CrossRef
35. 35Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International study: 1984-2002. Pediatrics. 2003;112:1523–1529. 36. 36Pletcher BA, Gross SJ, Monaghan KG, Driscoll DA, Watson MS. The future is now: carrier screening for all populations. Genet Med. 2008;10:33–36.
CrossRef
a National Human Genome Research Institute, National Institutes of Health, Bethesda, MD b Department of Family Medicine, Boston University Medical Center, Boston, MA Reprints: W. Gregory Feero MD, PhD, Chief, Genomic Healthcare Branch, National Human Genome Research Institute, Building 31, Room 4B09, 31 Center Dr, Bethesda, MD 20892
Supported in part by the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. Conflict of Interest: Benjamin D. Solomon, MD; Brian W. Jack, MD; and W. Gregory Feero, MD, PhD have no conflict of interest including grants, honoraria, advisory board membership, or share holdings. PII: S0002-9378(08)01095-8 doi:10.1016/j.ajog.2008.09.870 Published by Elsevier Inc. | |
|